Health and Life Science deals

Sep 28, 2017

LNC Therapeutics, a French company specializing in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, raised €6.5 million ($7.7 million) in Series C funding.

In the same category

Press / Medias

LNC Therapeutics selected by BNP Paribas for its innovative approach to beat obesity

Nov 12, 2019

more +

Press / Medias

Avec plus de 140 millions d’euros levés, les startups ne ratent pas leur rentrée

Sep 6, 2019

more +

Press / Medias

LNC Therapeutics raises €6.2 million for the clinical development of new generation gut microbiome...

Sep 5, 2019

more +